1. A 52-year-old man with opioid use disorder is being initiated on methadone maintenance therapy. His medical history includes pulmonary tuberculosis for which he has been taking rifampin (a potent inducer of CYP3A4 — a liver enzyme that dramatically increases its own activity when exposed to certain drugs, accelerating the metabolism of co-administered substrates) for the past three months. The addiction medicine specialist anticipates that this patient will require substantially higher methadone doses than typical to achieve therapeutic plasma levels. Three weeks after reaching a dose that appeared clinically adequate, rifampin is discontinued as his TB treatment is completed. Which of the following best describes the sequence of pharmacokinetic events and the clinical risk that follows rifampin discontinuation in this patient?
A) Rifampin discontinuation causes abrupt CYP2D6 upregulation that converts methadone to a toxic metabolite at an accelerated rate, producing normethadone accumulation and QTc prolongation within 24 hours
B) With rifampin present, CYP3A4 induction markedly accelerated methadone metabolism, requiring higher doses to maintain therapeutic plasma levels; when rifampin is discontinued, CYP3A4 activity returns toward baseline over 2 to 4 weeks, methadone clearance falls substantially, and plasma methadone concentrations rise progressively on the same dose — creating a serious risk of delayed opioid toxicity and respiratory depression as enzyme activity normalizes
C) Rifampin competitively inhibits methadone binding to plasma proteins during co-administration; discontinuation releases bound methadone into the free fraction simultaneously, producing an acute spike in free methadone concentration within hours of the last rifampin dose
D) Rifampin induces P-glycoprotein efflux at the blood-brain barrier during co-administration, reducing CNS methadone penetration; discontinuation removes this barrier effect and produces sudden CNS toxicity from methadone that was previously excluded from the brain
E) The pharmacokinetic interaction between rifampin and methadone is entirely reversible within 48 hours of rifampin discontinuation because CYP3A4 induction resolves rapidly; the primary clinical risk is opioid withdrawal in the 48-hour window before enzyme activity normalizes, not toxicity
ANSWER: B
Rationale:
This question asked you to reason through the full pharmacokinetic sequence of CYP3A4 induction by rifampin and its consequences when the inducer is withdrawn. Rifampin is among the most potent CYP3A4 inducers in clinical medicine, upregulating enzyme expression through activation of the pregnane X receptor (PXR — a nuclear receptor that controls CYP enzyme gene transcription). During rifampin co-administration, methadone is metabolized far more rapidly than normal, and doses must be substantially increased — often by 50 to 100% or more — to maintain the plasma concentrations necessary for therapeutic effect and suppression of withdrawal. When rifampin is discontinued, CYP3A4 enzyme levels return toward baseline, but this de-induction is a gradual process that takes 2 to 4 weeks as existing enzyme protein is degraded and not replaced. During this normalization period, methadone clearance falls progressively while the patient remains on the elevated dose that was calibrated for the induced state. The result is a slow but substantial rise in plasma methadone concentrations that may not produce obvious toxicity for days to weeks — precisely the delayed pattern that has caused fatalities in this clinical scenario. Close monitoring and proactive dose reduction as rifampin is tapered are essential.
Option A: Option A is incorrect because rifampin induces CYP3A4, not CYP2D6, and normethadone accumulation causing QTc prolongation within 24 hours is not an established consequence of rifampin discontinuation; the risk is methadone level rise, not a toxic metabolite surge.
Option C: Option C is incorrect because rifampin does not competitively inhibit methadone protein binding; plasma protein displacement is not the mechanism of the rifampin-methadone interaction and does not produce an acute free drug spike on discontinuation.
Option D: Option D is incorrect because while rifampin does induce P-glycoprotein, the dominant and clinically established mechanism of the interaction is hepatic CYP3A4-mediated methadone metabolism, not blood-brain barrier P-glycoprotein exclusion of methadone from the CNS.
Option E: Option E is incorrect because CYP3A4 de-induction after rifampin discontinuation takes 2 to 4 weeks, not 48 hours; the primary clinical risk is delayed toxicity as enzyme activity normalizes on a dose calibrated for the induced state, not a brief withdrawal window.
2. A 61-year-old woman with metastatic ovarian cancer is stable on transdermal fentanyl 50 mcg/hour patches for chronic pain management. She develops a urinary tract infection with fever to 39.8°C (103.6°F). Over the following 12 hours she becomes increasingly sedated, with a respiratory rate of 7 breaths per minute and miosis. Her fentanyl patch was applied 18 hours ago and is not due for replacement. No new medications have been started. Which of the following best explains the development of opioid toxicity in this patient?
A) Fever activates hepatic CYP3A4 through a heat-shock protein mechanism, paradoxically increasing fentanyl conversion to an active metabolite that accumulates and causes toxicity independent of transdermal absorption rate
B) High fever causes dermal vasoconstriction as a thermoregulatory response, trapping fentanyl within the subcutaneous depot and releasing it as a bolus when vasomotor tone normalizes during antipyretic treatment
C) The urinary tract infection has caused acute kidney injury, impairing renal clearance of fentanyl's active glucuronide metabolite, which accumulates to produce the observed toxicity
D) Fever causes increased cardiac output and systemic vasodilation, raising hepatic blood flow and reducing first-pass extraction of fentanyl absorbed from the patch, effectively increasing bioavailability
E) Elevated skin temperature from fever increases the rate of fentanyl release from the transdermal patch and enhances dermal blood flow and membrane permeability, substantially increasing the rate of fentanyl absorption into the systemic circulation and raising plasma fentanyl concentrations well above the therapeutic range established at baseline
ANSWER: E
Rationale:
This question asked you to identify the mechanism by which fever causes fentanyl toxicity in a patient on a stable transdermal patch dose. Transdermal drug delivery systems are highly temperature-sensitive. Fentanyl release from the patch membrane and diffusion through the stratum corneum both increase with skin temperature — a direct physical effect of heat on membrane fluidity, drug solubility in the patch matrix, and diffusion coefficients. Simultaneously, fever produces cutaneous vasodilation and increased dermal blood flow, which accelerates removal of absorbed fentanyl from the skin depot into the systemic circulation, maintaining a favorable concentration gradient for continued absorption. The combined effect is a substantial increase in the rate of fentanyl delivery — potentially 30 to 50% or more above the labeled rate — from a patch that is delivering an apparently stable dose under normal temperature conditions. This interaction is documented in fentanyl prescribing information, which warns against exposing patches to external heat sources (heating pads, electric blankets, heated water beds, sunbathing) and notes that fever above 40°C can produce clinically significant increases in absorption. The clinical implication is that patients on transdermal fentanyl who develop fever require close monitoring for opioid toxicity and may need temporary dose reduction or patch removal.
Option A: Option A is incorrect because heat-shock protein-mediated CYP3A4 activation producing a toxic active fentanyl metabolite is not an established mechanism; fentanyl's primary metabolite norfentanyl is inactive, and hepatic enzyme activation by fever is not a clinically recognized interaction pathway for transdermal fentanyl toxicity.
Option B: Option B is incorrect because fever causes cutaneous vasodilation, not vasoconstriction; the vasodilatory response increases, not traps, fentanyl absorption.
Option C: Option C is incorrect because fentanyl is not primarily renally cleared via an active glucuronide metabolite; its primary metabolite norfentanyl is inactive and its clearance is predominantly hepatic; acute kidney injury from a urinary tract infection in a previously healthy patient is unlikely to be severe enough to produce this presentation within 12 hours.
Option D: Option D is incorrect because fentanyl administered transdermally bypasses first-pass hepatic metabolism entirely — it enters the systemic venous circulation directly through the skin; changes in hepatic first-pass extraction are irrelevant to transdermal bioavailability.
3. A 58-year-old man with opioid use disorder, stable on buprenorphine-naloxone 16 mg/2 mg sublingual daily, is diagnosed with pancreatic cancer and develops severe pain rated 9/10. His oncologist prescribes oxycodone 10 mg every 4 hours for breakthrough pain. After two days the patient reports that the oxycodone provides virtually no pain relief. His buprenorphine dose has not been changed. Which of the following best explains the inadequate response to oxycodone and identifies the most appropriate management strategy?
A) Buprenorphine's exceptionally high mu (μ) receptor affinity and slow dissociation rate allow it to occupy the majority of available mu receptors at therapeutic doses; oxycodone — a full agonist — cannot competitively displace buprenorphine to achieve sufficient receptor occupancy for analgesia at standard doses; management options include discontinuing buprenorphine and transitioning to a full agonist opioid regimen, substantially increasing the full agonist dose to overcome competitive binding, or — increasingly preferred in cancer pain — continuing buprenorphine and titrating it to higher doses where it provides direct analgesia without the ceiling effect seen at lower doses
B) Oxycodone requires CYP2D6 conversion to oxymorphone for analgesic activity, and buprenorphine inhibits CYP2D6 competitively, blocking oxymorphone formation and rendering oxycodone inactive in all patients receiving buprenorphine maintenance therapy
C) The naloxone component of the buprenorphine-naloxone formulation accumulates systemically over weeks of sublingual use and reaches plasma concentrations sufficient to block oxycodone at mu receptors, independent of buprenorphine's receptor activity
D) Buprenorphine causes permanent mu receptor internalization and lysosomal degradation with chronic use, reducing total receptor density to a level at which full agonists cannot achieve analgesia regardless of dose
E) Oxycodone is a prodrug that requires conversion to oxymorphone by hepatic CYP2D6; buprenorphine's long half-life saturates CYP2D6 binding sites, reducing oxymorphone formation by competitive enzyme inhibition and explaining the absence of analgesic effect
ANSWER: A
Rationale:
This question asked you to explain why a full agonist opioid fails to provide analgesia in a patient on buprenorphine maintenance and to identify appropriate management. The mechanism is pharmacodynamic competitive binding at the mu receptor. Buprenorphine binds the mu receptor with extraordinarily high affinity — substantially higher than morphine, oxycodone, or most full agonists — and its dissociation from the receptor is very slow, with a receptor residence time measured in hours. At the 16 mg daily sublingual dose used in opioid use disorder treatment, buprenorphine occupies the great majority of available mu receptors throughout the CNS. When oxycodone is administered, it cannot effectively displace buprenorphine from receptors despite being a full agonist, because affinity determines competitive displacement and buprenorphine's affinity is superior. The result is that oxycodone cannot achieve the receptor occupancy required for meaningful analgesia at standard doses. Three management strategies are available in this situation: first, discontinue buprenorphine, allow washout, and transition fully to a full agonist regimen — acceptable but removes the addiction treatment framework and carries relapse risk; second, substantially increase the full agonist dose to attempt to overcome competitive binding through mass action — partially effective in some patients but requires very high doses; third — increasingly the preferred approach in cancer and other severe pain settings — continue buprenorphine and titrate it upward, recognizing that at higher doses buprenorphine itself provides effective analgesia through its partial agonism, supplemented by non-opioid analgesics and regional techniques.
Option B: Option B is incorrect because buprenorphine does not inhibit CYP2D6; the pharmacodynamic receptor competition is the established mechanism, not metabolic enzyme inhibition of oxymorphone formation.
Option C: Option C is incorrect because sublingual naloxone bioavailability is approximately 2 to 10%, and systemic naloxone accumulation to mu receptor-blocking plasma concentrations does not occur with chronic sublingual buprenorphine-naloxone use at standard doses; the naloxone component is clinically insignificant by the sublingual route.
Option D: Option D is incorrect because buprenorphine does not cause permanent mu receptor internalization and lysosomal degradation; receptor occupancy by buprenorphine is reversible, and receptor density recovers after buprenorphine washout.
Option E: Option E is incorrect because buprenorphine does not competitively inhibit CYP2D6 enzymatic activity; the interaction is at the receptor level, not the metabolic enzyme level, and the premise that buprenorphine saturates CYP2D6 binding sites is pharmacologically unfounded.
4. A 44-year-old woman with major depressive disorder is taking sertraline 150 mg daily (an SSRI — selective serotonin reuptake inhibitor that blocks neuronal serotonin reuptake transporters). She is prescribed tramadol 50 mg every 6 hours for chronic musculoskeletal pain. Genetic testing performed for an unrelated reason reveals she is a CYP2D6 poor metabolizer. Her psychiatrist reviews the medication combination and expresses concern. Which of the following most accurately characterizes the combined pharmacological risks in this specific patient?
A) CYP2D6 poor metabolizer status eliminates all tramadol analgesic activity and all serotonergic risk simultaneously, because both the opioid and serotonergic effects of tramadol depend entirely on CYP2D6 conversion to O-desmethyltramadol; this patient receives no benefit and faces no risk from tramadol
B) CYP2D6 poor metabolizer status increases tramadol's serotonergic risk because unconverted tramadol parent compound accumulates and is a more potent serotonin reuptake inhibitor than O-desmethyltramadol; combined with sertraline, this produces an amplified serotonin syndrome risk compared to a normal metabolizer
C) The combination is safe in CYP2D6 poor metabolizers because sertraline inhibits CYP2D6, and since this patient already has no CYP2D6 activity, sertraline has no pharmacokinetic effect on tramadol metabolism; the absence of O-desmethyltramadol formation means there is no opioid receptor activation and therefore no opioid-serotonin interaction risk
D) In this CYP2D6 poor metabolizer, O-desmethyltramadol (M1 — the active opioid metabolite) formation is markedly reduced, substantially diminishing the opioid analgesic component; however, tramadol parent compound accumulates to higher plasma levels due to reduced metabolic clearance and retains its serotonin and norepinephrine reuptake inhibition activity — meaning the serotonergic risk from combining elevated tramadol parent levels with sertraline persists and may be amplified, while analgesic efficacy is reduced
E) CYP2D6 poor metabolizer status converts tramadol from an analgesic to a pure serotonergic agent with no opioid activity; the combination with sertraline produces obligate serotonin syndrome requiring immediate discontinuation of both agents regardless of clinical symptoms
ANSWER: D
Rationale:
This question asked you to reason through the consequences of CYP2D6 poor metabolizer status for both the analgesic and serotonergic components of tramadol in a patient on an SSRI. Tramadol has two distinct pharmacological activities: weak mu opioid receptor agonism, which depends largely on CYP2D6-mediated O-demethylation to the active metabolite O-desmethyltramadol (M1); and inhibition of neuronal norepinephrine and serotonin reuptake, which is an intrinsic property of the tramadol parent compound itself and does not require metabolic conversion. In a CYP2D6 poor metabolizer, M1 formation is markedly reduced — the opioid analgesic component is substantially diminished and the patient derives less pain relief from the drug. However, because CYP2D6 is also a major metabolic clearance pathway for the parent tramadol compound, reduced CYP2D6 activity causes tramadol itself to accumulate to higher plasma concentrations than in a normal metabolizer. This elevated parent compound concentration enhances serotonin and norepinephrine reuptake inhibition. When combined with sertraline — which independently blocks serotonin reuptake — the combination carries a meaningful and potentially amplified risk of serotonin syndrome even though the opioid analgesic effect is reduced. The clinical implication is counterintuitive: poor metabolizer status in this combination reduces therapeutic benefit while maintaining or increasing the principal toxicity risk.
Option A: Option A is incorrect because tramadol's serotonergic activity is an intrinsic property of the parent compound, not dependent on CYP2D6 conversion; poor metabolizer status eliminates neither all activity nor all risk.
Option B: Option B is incorrect because the tramadol parent compound is not a more potent serotonin reuptake inhibitor than M1 on a per-molecule basis; the increased risk in poor metabolizers comes from parent compound accumulation increasing total serotonergic exposure, not from superior potency of the parent.
Option C: Option C is incorrect because the combination is not safe; the serotonergic risk from parent tramadol accumulation combined with sertraline persists regardless of whether sertraline has any additional pharmacokinetic effect on an already-absent CYP2D6 pathway.
Option E: Option E is incorrect because CYP2D6 poor metabolizer status does not produce obligate serotonin syndrome or require immediate discontinuation in the absence of clinical symptoms; it requires careful monitoring and consideration of alternative analgesics, but asymptomatic patients are not in serotonin syndrome simply by virtue of the combination.
5. A 49-year-old man with chronic low back pain has been on long-term high-dose opioid therapy. Over the past three months his pain scores have increased from 4/10 to 8/10 despite two sequential dose escalations. His physician increased the oxycodone dose each time, but pain worsened rather than improved. Physical examination reveals allodynia (pain from normally non-painful stimuli) in areas beyond his original pain distribution, and the character of his pain has changed from a localized aching to a diffuse burning quality. There is no evidence of disease progression or new pathology on imaging. Which of the following best distinguishes this clinical picture from opioid tolerance and identifies the correct management direction?
A) This presentation is consistent with opioid tolerance, in which mu receptor downregulation reduces analgesic efficacy proportionally to dose; the correct management is continued dose escalation using a fixed 25% increment protocol until the analgesic ceiling is re-established
B) This presentation is consistent with opioid-induced hyperalgesia (OIH) — a paradoxical state of central sensitization in which chronic high-dose opioid exposure increases rather than decreases pain sensitivity, mediated in part through NMDA receptor activation, dynorphin upregulation, and descending facilitation; unlike tolerance, in which dose escalation restores analgesia, dose escalation in OIH worsens the hyperalgesic state; correct management involves opioid dose reduction or rotation, addition of an NMDA antagonist such as ketamine or methadone, and multimodal non-opioid strategies
C) The diffuse allodynia and worsening pain with dose escalation indicate serotonin syndrome from opioid accumulation activating 5-HT2A receptors in the spinal cord; management requires cyproheptadine (a serotonin antagonist) and opioid discontinuation rather than dose adjustment
D) This is a presentation of opioid pseudoaddiction — undertreated pain driving drug-seeking behavior that mimics addiction; the correct response is to increase the opioid dose substantially and reassess pain control, as the behavioral features will resolve when analgesia is adequate
E) The change in pain character and distribution indicates development of opioid-induced peripheral neuropathy from direct neurotoxic effects of oxycodone metabolites on dorsal root ganglion neurons; opioid rotation to a non-neurotoxic agent such as buprenorphine is required
ANSWER: B
Rationale:
This question asked you to distinguish opioid-induced hyperalgesia from tolerance and identify appropriate management. The clinical features in this vignette — worsening pain despite dose escalation, allodynia beyond the original pain distribution, and a qualitative change in pain character to diffuse burning — are the hallmarks of opioid-induced hyperalgesia (OIH), a phenomenon that is mechanistically and clinically distinct from tolerance. Tolerance is receptor-level adaptation (downregulation, G-protein uncoupling) that reduces the analgesic effect of a given dose, requiring higher doses for the same effect; crucially, dose escalation in tolerance restores analgesia. OIH, by contrast, is a state of central sensitization in which the nervous system becomes paradoxically more pain-sensitive as a consequence of sustained opioid receptor activation. The proposed mechanisms include NMDA receptor upregulation and activation (leading to wind-up and central sensitization), increased spinal dynorphin release (which activates pronociceptive pathways), descending facilitation from brainstem pain-modulating circuits, and glial activation. The defining clinical feature of OIH — and the key discriminating factor from tolerance — is that dose escalation worsens rather than improves pain. Management involves reversing the hyperalgesic state: opioid dose reduction (which often paradoxically reduces pain), opioid rotation (particularly to methadone, which has NMDA antagonist activity), addition of NMDA receptor antagonists such as ketamine, and integration of non-opioid analgesic strategies.
Option A: Option A is incorrect because this presentation is not consistent with simple tolerance; the worsening pain with dose escalation, expanded distribution, and allodynia distinguish OIH from tolerance, and continued dose escalation with a fixed protocol is precisely the wrong management for OIH.
Option C: Option C is incorrect because serotonin syndrome does not present as chronic progressive allodynia with worsening pain scores over months; serotonin syndrome is an acute toxidrome with autonomic instability, neuromuscular abnormalities, and altered mental status — not a chronic pain sensitization state.
Option D: Option D is incorrect because pseudoaddiction refers to undertreated pain producing drug-seeking behavior, and the clinical features here — allodynia, expanded pain distribution, and worsening with dose escalation — are not explained by undertreated nociceptive pain; increasing the dose would worsen OIH.
Option E: Option E is incorrect because opioid-induced peripheral neuropathy from direct dorsal root ganglion neurotoxicity of oxycodone metabolites is not an established clinical entity; OIH is a central sensitization phenomenon, not a peripheral nerve toxicity syndrome.
6. A 39-year-old woman on methadone 110 mg daily for opioid use disorder presents for routine follow-up. An ECG obtained as part of annual monitoring reveals a QTc interval of 524 milliseconds (normal <450 ms in women). She takes no other QT-prolonging medications. Serum potassium is 3.2 mEq/L and magnesium is 1.6 mg/dL. She has been abstinent from illicit opioids for 14 months and reports the methadone program has been transformative for her recovery. Which of the following represents the most clinically appropriate and pharmacologically reasoned initial management strategy?
A) Immediately discontinue methadone and initiate buprenorphine-naloxone, as a QTc above 500 milliseconds in any patient on methadone is an absolute contraindication to continuation regardless of the clinical context or correctable contributing factors
B) Continue methadone at the current dose without modification; a QTc of 524 milliseconds in a woman is within normal biological variation and does not require intervention or reassessment
C) Address the correctable contributors first — replete potassium to ≥4.0 mEq/L and magnesium to ≥2.0 mg/dL, as electrolyte deficiencies (particularly hypokalemia and hypomagnesemia) independently prolong QTc by reducing the conductance of repolarizing potassium channels; repeat the ECG after correction; if QTc remains above 500 milliseconds after electrolyte optimization, reduce the methadone dose incrementally with repeat ECG monitoring, weighing the cardiac risk against the substantial risk of relapse and its consequences
D) Add prophylactic amiodarone to suppress ventricular arrhythmia risk while continuing methadone at the current dose, as antiarrhythmic therapy offsets hERG channel blockade through a complementary mechanism
E) Refer immediately to electrophysiology for implantable cardioverter-defibrillator (ICD) placement as primary prevention of torsades de pointes before any changes to the methadone regimen are made
ANSWER: C
Rationale:
This question asked you to apply pharmacological reasoning to the clinical management of methadone-associated QTc prolongation, integrating cardiac risk with the treatment context. A QTc of 524 milliseconds represents significant prolongation and carries real risk for torsades de pointes (TdP) — a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. However, the appropriate response is not automatic discontinuation, because two immediately correctable contributors are present: hypokalemia (potassium 3.2 mEq/L) and hypomagnesemia (magnesium 1.6 mg/dL). Potassium and magnesium are critical determinants of hERG channel conductance — the same channel that methadone blocks. Hypokalemia directly reduces hERG current by decreasing the electrochemical driving force for potassium efflux and by causing hERG channel inactivation; hypomagnesemia impairs membrane stabilization. Both independently prolong the QTc and together may account for a substantial portion of the observed prolongation beyond methadone's intrinsic contribution. Electrolyte repletion to target levels (K⁺ ≥4.0 mEq/L, Mg²⁺ ≥2.0 mg/dL) followed by ECG reassessment is the pharmacologically rational first step. If QTc remains above 500 milliseconds after correction, dose reduction with monitoring is appropriate, weighing the cardiac risk against the high risk of relapse and its clinical consequences — including overdose fatality risk — if methadone is abruptly discontinued in a patient with 14 months of successful recovery.
Option A: Option A is incorrect because QTc elevation above 500 milliseconds in a methadone patient is not an absolute contraindication to continuation regardless of context; correctable causes must be addressed first, and the decision to continue or reduce requires individualized risk-benefit analysis that explicitly includes relapse risk.
Option B: Option B is incorrect because a QTc of 524 milliseconds is not within normal biological variation; it is meaningfully prolonged and requires active management, not observation.
Option D: Option D is incorrect because amiodarone is itself a potent hERG channel blocker and QTc-prolonging agent; adding amiodarone to methadone would substantially increase the QTc and TdP risk, not mitigate it — this combination is contraindicated.
Option E: Option E is incorrect because ICD implantation is not indicated as the initial or primary management step for drug-induced QTc prolongation with correctable causes; it is a secondary prevention strategy for patients who have already survived TdP or VF, not a first-line intervention for a prolonged QTc.
7. A palliative care team is rotating a 67-year-old man from oral morphine to methadone for refractory cancer pain. His current total daily oral morphine equivalent (OME) dose is 480 mg. The team consults the Ripamonti equianalgesic conversion guideline, which recommends the following morphine-to-methadone ratios based on prior morphine dose: 30–90 mg/day = 4:1; 90–300 mg/day = 8:1; greater than 300 mg/day = 12:1. After selecting the appropriate ratio, they apply a further 25% reduction for incomplete cross-tolerance before prescribing. Which of the following correctly applies this calculation and identifies the appropriate starting methadone dose?
A) Using the >300 mg/day ratio of 12:1: 480 mg ÷ 12 = 40 mg methadone equianalgesic dose; applying 25% reduction: 40 mg × 0.75 = 30 mg methadone daily as the starting dose, divided into appropriate dosing intervals with upward titration guided by pain response and tolerance
B) Using the 90–300 mg/day ratio of 8:1 (selected because 480 mg represents the upper range of moderate dosing): 480 mg ÷ 8 = 60 mg methadone; applying 25% reduction: 60 mg × 0.75 = 45 mg methadone daily as the starting dose
C) Using the >300 mg/day ratio of 12:1: 480 mg ÷ 12 = 40 mg methadone; no cross-tolerance reduction is applied because methadone's NMDA antagonism fully compensates for incomplete cross-tolerance, making the full equianalgesic dose appropriate as the starting point
D) Using the 90–300 mg/day ratio of 8:1 and no cross-tolerance reduction because the patient's high prior opioid dose indicates maximal tolerance, making incomplete cross-tolerance pharmacologically impossible at this dose level: 480 mg ÷ 8 = 60 mg methadone daily as the starting dose
E) Using the >300 mg/day ratio of 12:1: 480 mg ÷ 12 = 40 mg; applying a 50% reduction rather than 25% because doses above 300 mg OME require a more conservative reduction: 40 mg × 0.50 = 20 mg methadone daily as the starting dose
ANSWER: A
Rationale:
This question asked you to correctly apply a dose-dependent equianalgesic conversion table followed by an incomplete cross-tolerance reduction. The patient's total daily OME of 480 mg places him in the greater than 300 mg/day tier, specifying a 12:1 morphine-to-methadone ratio. Dividing 480 mg by 12 yields 40 mg as the equianalgesic methadone dose. Applying the 25% incomplete cross-tolerance reduction: 40 mg × 0.75 = 30 mg methadone daily. This dose is then divided across an appropriate dosing interval — typically every 8 hours for pain management (10 mg every 8 hours in this case) — and titrated upward no more frequently than every 5 to 7 days given methadone's long and variable half-life and the risk of delayed accumulation. The two-step process — selecting the correct ratio tier and then applying the cross-tolerance reduction — is the standard clinical workflow for methadone rotation and reflects both the dose-dependent NMDA contribution to methadone's potency (which drives the increasing ratio at higher prior opioid doses) and the pharmacodynamic principle that tolerance to one opioid does not fully transfer to a structurally distinct one.
Option B: Option B is incorrect because 480 mg falls unambiguously in the greater than 300 mg/day tier; selecting the 8:1 ratio applicable to the 90–300 mg/day range underestimates methadone's effective potency at this prior opioid dose level and risks toxicity from a dose that is too high.
Option C: Option C is incorrect because methadone's NMDA antagonism does not eliminate the need for the incomplete cross-tolerance reduction; it is one component of why the ratio increases at higher prior doses, but it does not substitute for or override the cross-tolerance dose reduction, which accounts for the patient's residual sensitivity to methadone.
Option D: Option D is incorrect because high prior opioid dose does not make incomplete cross-tolerance pharmacologically impossible; incomplete cross-tolerance occurs regardless of how tolerant the patient is to the prior opioid, and the higher the prior dose the more important — not less important — conservative dosing becomes given the steeper methadone potency at that dose tier.
Option E: Option E is incorrect because while a 50% reduction is used in some protocols, particularly at very high prior opioid doses or in frail patients, the question specifies a 25% reduction protocol; applying 50% without clinical justification beyond the dose range is not consistent with the stated protocol, and 20 mg is likely to undertreated the patient's pain.
8. An anesthesiologist is planning a remifentanil-based anesthetic for a 34-year-old woman scheduled for a 3-hour laparoscopic procedure. Pre-operative assessment reveals she has a known dibucaine number of 20 (normal >70), indicating homozygous atypical pseudocholinesterase (also called butyrylcholinesterase — a plasma enzyme distinct from acetylcholinesterase that metabolizes succinylcholine and some other ester-containing drugs). The anesthesiologist asks the resident whether pseudocholinesterase deficiency will affect remifentanil's pharmacokinetics. Which of the following is the most accurate answer?
A) Pseudocholinesterase deficiency will markedly prolong remifentanil's duration of action because pseudocholinesterase is the primary enzyme responsible for remifentanil hydrolysis in plasma, and its absence will cause remifentanil to accumulate to toxic concentrations during a 3-hour infusion
B) Pseudocholinesterase deficiency will mildly prolong remifentanil's half-life from 3–10 minutes to approximately 20–30 minutes because pseudocholinesterase contributes approximately 30% of total remifentanil esterase activity, with nonspecific tissue esterases providing the remainder
C) Pseudocholinesterase deficiency is relevant only for the naloxone component co-administered with remifentanil in standard formulations; remifentanil itself is metabolized exclusively by acetylcholinesterase, which is unaffected by the dibucaine number
D) Pseudocholinesterase deficiency will cause remifentanil to be rerouted through hepatic CYP3A4 metabolism, extending the half-life to 2 to 4 hours and requiring a 75% infusion rate reduction to prevent accumulation
E) Pseudocholinesterase deficiency has no clinically significant effect on remifentanil pharmacokinetics because remifentanil is metabolized by nonspecific plasma and tissue esterases — a broad family of ubiquitous hydrolytic enzymes distinct from pseudocholinesterase — that are present in abundance throughout blood and tissues and are not affected by the pseudocholinesterase genetic variants that prolong succinylcholine effect; remifentanil's half-life of 3–10 minutes is preserved in pseudocholinesterase-deficient patients
ANSWER: E
Rationale:
This question asked you to apply precise knowledge of remifentanil's metabolic pathway to a clinical scenario involving pseudocholinesterase deficiency. This is a clinically important distinction that is frequently misunderstood. Remifentanil contains an ester linkage in its structure that is susceptible to hydrolysis, but the enzymes responsible for its cleavage are nonspecific esterases — a large family of hydrolytic enzymes present throughout plasma, erythrocytes, and tissue (particularly muscle and intestine) that are genetically and structurally distinct from pseudocholinesterase (butyrylcholinesterase). Pseudocholinesterase is a specific plasma enzyme encoded by the BCHE gene; genetic variants producing atypical pseudocholinesterase (as indicated by a low dibucaine number) markedly impair hydrolysis of succinylcholine, mivacurium, and cocaine — substrates for which pseudocholinesterase is the primary or sole metabolizing enzyme. Remifentanil, however, is not a pseudocholinesterase substrate. Nonspecific esterase activity is not altered by BCHE gene variants, and remifentanil's half-life remains 3 to 10 minutes in pseudocholinesterase-deficient patients — a fact confirmed in pharmacokinetic studies. This patient's pseudocholinesterase deficiency has direct implications for succinylcholine use (which must be avoided or used with great caution) but does not require any modification of the remifentanil infusion protocol.
Option A: Option A is incorrect because pseudocholinesterase is not the primary enzyme responsible for remifentanil hydrolysis; nonspecific esterases are, and pseudocholinesterase deficiency does not prolong remifentanil's duration of action.
Option B: Option B is incorrect because pseudocholinesterase does not contribute 30% of total remifentanil esterase activity; its contribution to remifentanil metabolism is negligible, and the half-life is not prolonged to 20–30 minutes in pseudocholinesterase-deficient patients.
Option C: Option C is incorrect because remifentanil does not contain a naloxone component and is not metabolized by acetylcholinesterase; it is metabolized by nonspecific esterases.
Option D: Option D is incorrect because remifentanil is not rerouted through CYP3A4 when esterase activity is normal; CYP3A4 plays no significant role in remifentanil metabolism, and no infusion rate reduction is required in pseudocholinesterase-deficient patients.
9. A 55-year-old man with chronic pain is stable on controlled-release oxycodone 40 mg every 12 hours. He develops a systemic Candida infection and is started on ketoconazole — a potent CYP3A4 inhibitor (an agent that blocks the liver enzyme responsible for oxycodone N-demethylation to noroxycodone). Forty-eight hours later he is markedly sedated with a respiratory rate of 6 breaths per minute. His oxycodone dose was not changed. A colleague asks how the magnitude of this interaction compares to the opposite scenario — a patient on the same oxycodone dose starting rifampin, a potent CYP3A4 inducer. Which of the following most accurately characterizes both interactions and their directional effects on oxycodone plasma levels?
A) Both interactions are pharmacodynamic rather than pharmacokinetic; ketoconazole increases oxycodone's mu receptor affinity through allosteric receptor modulation, while rifampin decreases it through competitive receptor antagonism
B) The two interactions are equivalent in magnitude but opposite in direction: ketoconazole doubles oxycodone plasma levels while rifampin halves them, producing symmetrical risks of toxicity and withdrawal respectively
C) Ketoconazole inhibits CYP3A4 and raises oxycodone plasma levels, but the magnitude is modest (less than 20% increase) because oxycodone's primary metabolic pathway is CYP2D6; rifampin induces CYP3A4 and modestly reduces oxycodone levels, but again the effect is limited by CYP2D6 providing an alternative clearance route
D) Both interactions operate through CYP3A4 but are asymmetric in clinical risk: ketoconazole inhibition raises oxycodone plasma levels substantially — published studies demonstrate a 2 to 3-fold increase in oxycodone AUC (area under the plasma concentration-time curve, a measure of total drug exposure) — creating an acute toxicity risk; rifampin induction reduces oxycodone plasma levels substantially, potentially by 50% or more, creating a risk of inadequate analgesia and opioid withdrawal; both require proactive dose adjustment and close monitoring
E) Ketoconazole raises oxycodone plasma levels by inhibiting CYP2D6 and blocking conversion to oxymorphone; rifampin lowers levels by inducing CYP2D6 and accelerating conversion to oxymorphone; the net clinical effect of both is minimal because oxymorphone and oxycodone have equivalent analgesic potency
ANSWER: D
Rationale:
This question asked you to characterize and compare two opposite CYP3A4 drug interactions with oxycodone and to assess their asymmetric clinical risk profiles. Oxycodone undergoes two major hepatic metabolic pathways: CYP3A4-mediated N-demethylation to noroxycodone (the major pathway by flux, responsible for approximately 45% of oxycodone clearance) and CYP2D6-mediated O-demethylation to oxymorphone (a minor pathway by flux but producing a more potent metabolite). Ketoconazole, as a potent CYP3A4 inhibitor, substantially reduces the N-demethylation pathway, reducing total oxycodone clearance and raising plasma oxycodone concentrations. Published pharmacokinetic studies demonstrate that ketoconazole co-administration increases oxycodone AUC by approximately 2 to 3-fold — a clinically dangerous magnitude that explains the toxicity observed in this patient. Rifampin, as a potent CYP3A4 inducer, has the opposite effect: CYP3A4 upregulation accelerates oxycodone N-demethylation, reducing oxycodone plasma concentrations substantially — by 50 to 86% in published studies — producing loss of analgesia and potential withdrawal. The two interactions are therefore directionally opposite but share the same enzymatic mechanism. Importantly, neither interaction is symmetric in its absolute plasma level effect, and both require proactive management: oxycodone dose reduction when ketoconazole is started, and dose increase (with careful re-titration after rifampin is stopped) when rifampin is used.
Option A: Option A is incorrect because both interactions are pharmacokinetic, not pharmacodynamic; ketoconazole and rifampin do not alter mu receptor affinity or act as receptor modulators.
Option B: Option B is incorrect because the interactions are not equivalent in magnitude; the induction effect of rifampin on oxycodone levels (50–86% reduction) is larger in absolute terms than the inhibition effect of ketoconazole (2 to 3-fold increase as a ratio, but the magnitude depends on baseline levels); the symmetrical description oversimplifies a clinically important asymmetry.
Option C: Option C is incorrect because CYP3A4 is actually oxycodone's major metabolic pathway by flux, not a minor one; CYP2D6 is the minor pathway by flux; the claim that CYP3A4 interactions are modest because CYP2D6 provides an alternative route understates the clinical significance of CYP3A4 inhibition and induction for oxycodone.
Option E: Option E is incorrect because the CYP enzymes are reversed; ketoconazole inhibits CYP3A4 (not CYP2D6), and rifampin induces CYP3A4 (not CYP2D6); additionally, oxymorphone is substantially more potent than oxycodone at the mu receptor, so the claim of equivalent analgesic potency is pharmacologically inaccurate.
10. A 29-year-old woman undergoes pharmacogenomic testing and is found to be a CYP2D6 poor metabolizer (carrying two non-functional CYP2D6 alleles). She presents with moderate acute pain from a dental extraction and the dentist prescribes codeine 30 mg every 4 to 6 hours as needed. She returns two days later reporting no meaningful pain relief despite taking the maximum recommended doses. She asks for "something stronger." Which of the following best explains her lack of response to codeine and identifies the most pharmacologically appropriate alternative?
A) CYP2D6 poor metabolizers accumulate codeine to toxic plasma levels because they cannot clear the parent compound; she should be switched to a lower dose of codeine to reduce accumulation while preserving the small residual analgesic effect from unchanged codeine
B) Codeine is a prodrug that depends on CYP2D6-mediated O-demethylation to morphine for virtually all of its analgesic activity; in a CYP2D6 poor metabolizer this conversion is negligible, producing little or no analgesia despite full doses of codeine; an appropriate alternative is a non-CYP2D6-dependent analgesic such as ibuprofen (an NSAID — non-steroidal anti-inflammatory drug), acetaminophen, or an opioid that does not require CYP2D6 activation for analgesic efficacy, such as oxycodone or morphine
C) CYP2D6 poor metabolizers convert codeine exclusively to codeine-6-glucuronide, an active metabolite with analgesic potency comparable to morphine; her lack of response indicates opioid tolerance rather than a metabolic deficit, and dose escalation is appropriate
D) CYP2D6 poor metabolizer status causes codeine to be redirected entirely through CYP3A4 to produce norcodeine, which is a pure mu receptor antagonist; this explains not only her lack of analgesia but also why she should avoid all opioids metabolized through CYP3A4
E) The lack of analgesic response reflects codeine-specific receptor polymorphism rather than a metabolic deficit; her mu opioid receptors have reduced affinity for morphine at the genetic level, and tramadol — which does not require mu receptor morphine binding — would provide effective analgesia through its norepinephrine reuptake mechanism alone
ANSWER: B
Rationale:
This question asked you to apply knowledge of codeine's prodrug status and CYP2D6 pharmacogenetics to a clinical management decision. Codeine itself has essentially no direct analgesic activity at the mu opioid receptor — its clinical effect depends almost entirely on hepatic CYP2D6-mediated O-demethylation to morphine. In a patient homozygous for non-functional CYP2D6 alleles (a poor metabolizer), this conversion is negligible; plasma morphine levels after standard codeine doses are near zero, and the patient experiences minimal or no analgesia despite adequate codeine exposure. This explains precisely why taking the maximum recommended dose produced no benefit: the dose ceiling was not the limiting factor — the absence of the activating enzyme was. The appropriate clinical response is to switch to an analgesic that does not require CYP2D6 conversion for activity. Non-opioid options include NSAIDs and acetaminophen, which are appropriate for dental pain. If opioid analgesia is needed, agents such as morphine, hydromorphone, or oxycodone provide direct mu receptor activity that does not depend on CYP2D6 conversion — though for oxycodone, CYP2D6 does contribute to the formation of the more potent oxymorphone metabolite, so morphine or hydromorphone may be preferable choices in a poor metabolizer requiring opioid analgesia.
Option A: Option A is incorrect because CYP2D6 poor metabolizers do not accumulate codeine to toxic plasma levels through impaired clearance; codeine itself is cleared by other pathways including CYP3A4 and glucuronidation; the problem is failure to generate morphine, not parent drug toxicity.
Option C: Option C is incorrect because codeine-6-glucuronide is not a potent analgesic metabolite comparable to morphine; it has weak opioid activity and does not compensate for absent CYP2D6 conversion; the lack of response is a metabolic deficit, not tolerance.
Option D: Option D is incorrect because CYP3A4 converts codeine to norcodeine, which has no significant mu receptor antagonist activity; norcodeine is a relatively inactive metabolite, and CYP3A4 metabolism of codeine does not produce a mu antagonist that would interfere with other opioids metabolized by CYP3A4.
Option E: Option E is incorrect because the problem is metabolic — absent CYP2D6 conversion to morphine — not a receptor affinity polymorphism; and tramadol is not appropriate here because it also depends on CYP2D6 for its active opioid metabolite (M1), and would face the same efficacy deficit in a CYP2D6 poor metabolizer.
11. A 74-year-old man with an eGFR of 22 mL/min/1.73m² was admitted 4 days ago for hip fracture repair and has been receiving meperidine 75 mg IV every 4 hours for postoperative pain. He has received a total of 24 doses. This morning he developed repetitive myoclonic jerks (brief, involuntary muscle twitches) of his upper extremities that have now progressed to a generalized tonic-clonic seizure lasting 90 seconds. The bedside nurse reaches for naloxone. A senior resident intervenes and administers lorazepam instead. Which of the following most precisely explains why lorazepam is the correct acute intervention and naloxone would have been inappropriate — and potentially harmful — in this scenario?
A) Normeperidine — meperidine's N-demethylated metabolite — accumulates with repeated meperidine dosing and reaches toxic concentrations in renal impairment due to markedly prolonged clearance; normeperidine exerts its neurotoxicity through non-opioid CNS stimulant mechanisms including inhibition of GABA-A receptor-mediated inhibition and possibly direct proconvulsant channel activity; naloxone has no activity at these non-opioid targets and cannot terminate normeperidine-induced seizures; moreover, naloxone reverses meperidine's residual mu receptor-mediated CNS depression, unmasking the full stimulant effect of accumulated normeperidine and potentially worsening seizure severity; lorazepam — a benzodiazepine that enhances GABA-A receptor chloride conductance — directly counteracts the GABAergic deficit produced by normeperidine and is the appropriate antiepileptic intervention
B) Meperidine itself — not normeperidine — crosses the blood-brain barrier preferentially in patients with renal impairment due to reduced albumin binding and causes seizures by directly blocking NMDA receptors; naloxone reverses opioid effects but does not affect NMDA receptor activity, making benzodiazepine therapy appropriate as an NMDA-independent seizure suppressor
C) The seizure is caused by acute opioid withdrawal from relative underdosing over 4 days of therapy; naloxone would worsen the withdrawal-mediated seizure by precipitating full withdrawal; lorazepam suppresses the autonomic and neurological features of opioid withdrawal including seizure activity through GABA-A modulation
D) Normeperidine accumulates and causes seizures by activating kappa (κ) opioid receptors in cortical neurons; naloxone has poor kappa receptor affinity at standard doses and fails to reverse kappa-mediated effects; lorazepam provides seizure control through a non-opioid receptor mechanism
E) The seizure represents serotonin syndrome triggered by meperidine's serotonin reuptake inhibition after 4 days of dosing; naloxone does not reverse serotonin syndrome; lorazepam treats the neuromuscular component of serotonin syndrome and is the correct immediate intervention
ANSWER: A
Rationale:
This question asked you to explain both the mechanism of normeperidine neurotoxicity and the pharmacological rationale for benzodiazepine over naloxone as acute treatment. Normeperidine is produced by N-demethylation of meperidine through hepatic CYP enzymes and has a half-life of 15 to 20 hours — three to five times longer than meperidine itself. With repeated meperidine dosing, normeperidine accumulates progressively; in a patient with an eGFR of 22 mL/min/1.73m², renal clearance of normeperidine is markedly impaired, and 24 doses over 4 days is more than sufficient to produce toxic accumulation. Normeperidine's neurotoxicity operates through mechanisms entirely distinct from opioid receptor activity — it is not a mu, kappa, or delta opioid receptor agonist at clinically relevant concentrations. Its proconvulsant mechanism involves inhibition of GABAergic inhibitory interneurons (reducing inhibitory tone in cortical and subcortical circuits) and possibly direct membrane effects on excitatory channels. Naloxone is a pure competitive opioid receptor antagonist with no activity at the non-opioid targets mediating normeperidine toxicity; it cannot terminate these seizures. Critically, naloxone will reverse meperidine's residual mu receptor-mediated sedation and CNS depression — effects that were partially attenuating normeperidine's stimulant activity — potentially unmasking the full proconvulsant effect and worsening seizure severity. Lorazepam, by enhancing GABA-A receptor chloride conductance through the benzodiazepine binding site, directly counteracts the GABAergic deficit central to normeperidine's mechanism and is the pharmacologically rational choice. Meperidine must also be discontinued immediately.
Option B: Option B is incorrect because it is normeperidine — not the parent meperidine — that is responsible for the seizures; and NMDA receptor blockade by meperidine is not the established mechanism of meperidine-associated neurotoxicity.
Option C: Option C is incorrect because this is not an opioid withdrawal seizure; the patient has been receiving meperidine regularly for 4 days and is not withdrawing; the mechanism is normeperidine accumulation, not undertreatment.
Option D: Option D is incorrect because normeperidine does not exert its neurotoxicity through kappa opioid receptor activation; its mechanism is non-opioid receptor-mediated CNS stimulation through GABAergic disinhibition.
Option E: Option E is incorrect because while meperidine does inhibit serotonin reuptake, the clinical timeline and presentation here — myoclonus progressing to generalized seizure after 4 days of regular dosing with renal impairment — are characteristic of normeperidine accumulation, not acute serotonin syndrome; serotonin syndrome typically presents within hours of drug initiation or dose change, not after 4 days of stable dosing.
12. A 63-year-old man with opioid use disorder, stable on buprenorphine 24 mg sublingual daily, develops locally advanced pancreatic cancer with severe pain rated 9 to 10/10. His oncologist attempts to add hydromorphone for breakthrough pain without success — the patient reports no relief. The palliative care team is consulted. They note that buprenorphine's analgesic dose-response at doses used in addiction treatment differs from its effect at higher doses. Which of the following most accurately describes the pharmacodynamic basis for the failed hydromorphone trial and the most appropriate management pathway?
A) Buprenorphine at 24 mg daily has fully saturated all available mu receptors with irreversible binding; no additional opioid can provide analgesia until buprenorphine is fully eliminated from the body, which requires 7 to 10 days of washout before any opioid therapy can be initiated
B) The hydromorphone failure is due to buprenorphine-induced mu receptor downregulation that is proportional to dose; at 24 mg, receptor density has fallen to 15% of baseline, and no dose of any opioid can restore analgesia until receptor density recovers over 4 to 6 weeks after buprenorphine discontinuation
C) Buprenorphine at 24 mg daily causes complete cross-tolerance to all opioids through a shared receptor mechanism; hydromorphone must be given at 20 times the normal dose to overcome cross-tolerance, making it impractical; methadone is preferred because its NMDA antagonism bypasses the mu receptor entirely
D) Buprenorphine's high mu receptor affinity blocks hydromorphone from achieving adequate receptor occupancy for breakthrough analgesia at standard doses; the preferred management strategy is to continue buprenorphine and increase it to higher analgesic doses (buprenorphine provides effective analgesia in its own right at doses up to 32 mg or higher, without a ceiling on analgesia at these doses in severe pain), supplement with non-opioid analgesics and regional techniques, and consider transition to a full agonist regimen if pain remains uncontrolled — recognizing that this decision requires weighing analgesic need against relapse risk in the addiction treatment context
E) Buprenorphine selectively blocks kappa receptors at doses above 16 mg daily, converting from a partial mu agonist to a pure kappa antagonist; the hydromorphone failure is due to kappa receptor blockade preventing the descending inhibitory pathway activation that hydromorphone normally relies on for analgesia
ANSWER: D
Rationale:
This question asked you to integrate buprenorphine's receptor pharmacology with its clinical use in a patient who has both opioid use disorder and severe cancer pain. The failure of hydromorphone in this patient reflects the same mechanism discussed in Q3 — buprenorphine's extraordinarily high mu receptor affinity prevents full agonists from achieving the receptor occupancy required for analgesia at standard doses. At 24 mg daily, buprenorphine occupies a large proportion of available mu receptors and its slow dissociation rate means hydromorphone cannot effectively compete. The key pharmacological insight is that buprenorphine itself is not without analgesic activity at these doses; as a partial agonist, it produces meaningful analgesia, and at doses above those typically used in addiction treatment (which are optimized for withdrawal suppression rather than analgesia), buprenorphine's analgesic effect continues to increase. There is no ceiling on analgesia from buprenorphine at doses up to 32 mg sublingual and beyond in severe cancer pain — the partial agonist ceiling effect is primarily on respiratory depression, not on analgesia in opioid-tolerant patients. The preferred approach in cancer pain settings is therefore to continue and potentially increase buprenorphine, integrate non-opioid multimodal strategies (NSAIDs, corticosteroids, ketamine, regional nerve blocks), and reserve full agonist transition for cases of truly refractory pain — a decision that carries relapse risk implications requiring careful discussion with the patient and addiction medicine team.
Option A: Option A is incorrect because buprenorphine binding to mu receptors is reversible, not irreversible; a 7 to 10 day washout to complete elimination is not required, and the concept of "full saturation preventing any analgesia" mischaracterizes the competitive and reversible nature of receptor occupancy.
Option B: Option B is incorrect because buprenorphine does not cause permanent proportional mu receptor downregulation requiring weeks to recover; receptor density changes with buprenorphine are reversible and do not reduce available receptors to 15% of baseline.
Option C: Option C is incorrect because buprenorphine's cross-tolerance to full agonists does not require a fixed 20-fold dose multiplier for all opioids; and methadone's NMDA antagonism does not bypass the mu receptor — it is still primarily a mu agonist and would face the same receptor competition issue in this patient.
Option E: Option E is incorrect because buprenorphine does not selectively convert to a pure kappa antagonist at doses above 16 mg; its kappa antagonist activity is present at all clinical doses and is not dose-threshold-dependent; hydromorphone failure is not explained by kappa receptor blockade.
13. A 55-year-old woman with chronic cancer pain has been receiving intravenous hydromorphone 2 mg every 4 hours (total 12 mg IV daily) via a home pump. Her implanted port is being removed due to infection, and the team needs to transition her to oral opioids. The equianalgesic table gives IV hydromorphone 1.5 mg = oral oxycodone 20 mg. The team plans to apply a 30% incomplete cross-tolerance reduction to the calculated equianalgesic dose. Which of the following correctly performs the full conversion and identifies the appropriate starting oral oxycodone daily dose?
A) Total IV hydromorphone daily: 12 mg; equianalgesic oral oxycodone: 12 mg ÷ 1.5 mg × 20 mg = 160 mg oral oxycodone daily; applying 30% reduction: 160 mg × 0.70 = 112 mg oral oxycodone daily — rounded to 120 mg for practical dosing
B) Total IV hydromorphone daily: 12 mg; equianalgesic oral oxycodone using a simplified 1:10 ratio (IV hydromorphone to oral oxycodone): 12 mg × 10 = 120 mg oral oxycodone daily; no cross-tolerance reduction applied because IV-to-oral route conversions do not require incomplete cross-tolerance adjustment
C) Total IV hydromorphone daily: 12 mg; equianalgesic oral oxycodone: (12 mg ÷ 1.5 mg) × 20 mg = 160 mg oral oxycodone daily; applying 30% reduction for incomplete cross-tolerance: 160 mg × 0.70 = 112 mg oral oxycodone daily as the starting dose, to be divided across appropriate dosing intervals and titrated upward based on pain response and tolerability
D) Total IV hydromorphone daily: 12 mg; convert to oral hydromorphone first using IV:oral hydromorphone ratio of 1:5 = 60 mg oral hydromorphone daily; then convert oral hydromorphone to oral oxycodone using a 1:1.5 ratio = 90 mg oral oxycodone daily; apply 30% reduction: 90 mg × 0.70 = 63 mg oral oxycodone daily
E) The equianalgesic table cannot be applied across different drugs and routes simultaneously; the correct approach is first to convert IV hydromorphone to IV oxycodone using a potency ratio of 4:1, then separately apply the oral bioavailability correction for oxycodone of 60–87%, then apply the cross-tolerance reduction to the final figure
ANSWER: C
Rationale:
This question asked you to correctly perform a two-step equianalgesic conversion involving both a drug change and a route change, followed by an incomplete cross-tolerance dose reduction. Step 1: Establish total daily IV hydromorphone dose — 2 mg every 4 hours × 6 doses = 12 mg IV hydromorphone daily. Step 2: Apply the equianalgesic table directly, which gives the conversion factor as IV hydromorphone 1.5 mg = oral oxycodone 20 mg. To convert 12 mg IV hydromorphone: (12 mg ÷ 1.5 mg) × 20 mg = 8 × 20 mg = 160 mg oral oxycodone as the equianalgesic dose. Step 3: Apply the 30% incomplete cross-tolerance reduction: 160 mg × 0.70 = 112 mg oral oxycodone daily as the starting dose. This dose would typically be divided — for example, as controlled-release oxycodone 60 mg every 12 hours (120 mg) as a practical rounding — with upward titration guided by pain control and tolerability. The incomplete cross-tolerance reduction is applied here because this involves a change of opioid drug (hydromorphone to oxycodone), not merely a route change of the same drug; the patient has tolerance to hydromorphone that does not fully transfer to oxycodone. Option A arrives at the correct equianalgesic dose of 160 mg and applies the 30% reduction correctly to get 112 mg, but then incorrectly rounds up to 120 mg rather than staying at or below 112 mg; rounding upward after a safety-motivated reduction defeats the purpose of the reduction and is incorrect practice.
Option B: Option B is incorrect because it uses a simplified 1:10 ratio that does not match the stated equianalgesic table values and omits the cross-tolerance reduction; IV-to-oral conversions involving a drug change do require incomplete cross-tolerance adjustment.
Option D: Option D is incorrect because it introduces an unnecessary intermediate step — converting IV hydromorphone to oral hydromorphone first — using ratios not given in the question; direct application of the stated IV hydromorphone to oral oxycodone table values is the correct and more reliable approach when the table provides the direct conversion.
Option E: Option E is incorrect because equianalgesic tables are specifically designed to handle simultaneous drug and route conversions in one step using validated clinical ratios; the multi-step reconstruction described in this option introduces additional sources of error and is not the standard clinical method when a direct table conversion is available.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.